Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. - Wikidata - awgldk - TriplyDB

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q34239784

about

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.Red carpeting the newer antidiabetics.Spectrophotometric methods based on charge transfer complexation reactions for the determination of saxagliptin in bulk and pharmaceutical preparation.

P2860

Q28553675-1F6D4ADD-0339-42BB-AC60-3AD4AFDCE160 Q35411329-AF4D3EF3-37CF-48E0-9059-3609ED54E00E Q36139126-7777073E-4500-41F1-9AF9-9A5B856E424C Q36785098-EC5C5E7F-5D09-46AA-85B4-CCBC74B16E6B Q38013105-AECE6EF5-424C-447F-ADB2-23E09508E583 Q39547343-E3198A62-B174-4014-97A6-095FB45EA872

P2860

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q34239784

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@ast

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@en

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@nl

type

label

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@ast

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@en

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@nl

prefLabel

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@ast

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@en

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@nl

P1433

Q34239784-0DEA6EA2-5BD0-4079-9D28-7B014D517941

P1476

Q34239784-F01ADABB-4AF2-42CA-82DA-8E1A5EC612EB

P2093

Q34239784-5E82030C-D141-4756-9E02-8762A5CB0E2B

Q34239784-9DB3B3EB-38F6-411D-A2CD-17CDF16976F9

P2860

Q34239784-0342E957-7564-48EC-A6DB-56AF79E12F39

Q34239784-0A2C8C0F-B7CF-482B-94A1-B85B7A71215C

Q34239784-0A4CA97B-2F27-4947-B925-E31BE225F324

Q34239784-0B1A364A-D945-4EAC-959A-108497FF073F

Q34239784-10C3832F-4520-4ED9-B6B3-7460D877F5F9

Q34239784-149BB71E-552A-4A82-8CFD-5B5C6D08475D

Q34239784-149D813B-E536-4588-A710-CC125FE34BD0

Q34239784-1D276DFC-68CE-4ADB-A729-E1EFE333E007

Q34239784-23235548-6584-47AE-8E2B-54A284A6C3AC

Q34239784-26A3330A-1671-4DA0-AE8F-66126E8624D1

P304

Q34239784-CDEEA671-6375-4650-A363-E03986834A96

P31

Q34239784-A45866A1-2D31-448D-A02F-289826AE8496

P407

Q34239784-74448660-47FD-4933-87BE-25E7E065BF7E

P478

Q34239784-2B553519-4306-4D4D-A16E-7A5CB7AC588A

P577

Q34239784-56A34723-0CC4-4C36-AF96-19F349BECF89

P698

Q34239784-C8D7B062-0F68-49B7-BE7B-34345CAE8E64

P921

Q34239784-270B0646-71E1-41A2-9B89-EE1EB8B76363

Q34239784-3CE66EFB-6191-441A-8D5C-4643AFE84A13

P932

Q34239784-781D2CC0-D3EC-4BB1-A5D3-B2286A2B0253

P1433

P1476

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

@en

P2093

Kristen Kulasa

http://www.w3.org/2001/XMLSchema#string

Steven Edelman

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Defining the genetic contribution of type 2 diabetes mellitus.

The biology of incretin hormones.

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.

P304

23-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21042540

http://www.w3.org/2001/XMLSchema#string

P921

saxagliptin hydrate

type-2 diabetes

P932

2963920

http://www.w3.org/2001/XMLSchema#string